Diabetes, Metabolic Syndrome and Obesity (Mar 2024)

The Anatomic and Functional Outcomes of Ozurdex-Aided Vitrectomy in Proliferative Diabetic Retinopathy

  • Wang M,
  • Luan R,
  • Liu B,
  • Gong Y,
  • Zhao J,
  • Chen X,
  • Yang Q,
  • Liu J,
  • Liu J,
  • Shao Y,
  • Li X

Journal volume & issue
Vol. Volume 17
pp. 1199 – 1213

Abstract

Read online

Manqiao Wang,* Rong Luan,* Boshi Liu, Yi Gong, Jinzhi Zhao, Xiteng Chen, Qianhui Yang, Jingjie Liu, Juping Liu, Yan Shao, Xiaorong Li Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin, People’s Republic of China*These authors contributed equally to this workCorrespondence: Yan Shao; Xiaorong Li, Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital, Tianjin, People’s Republic of China, Tel +86 17622651170; +86 18622818042, Email [email protected]; [email protected]: To investigate the 3-months outcomes of patients who underwent intraoperative intravitreal injection of Ozurdex for proliferative diabetic retinopathy (PDR).Methods: This is a prospective randomized controlled clinical trial (ChiCTR2100043399). Seventy-one patients with PDR who had indications for surgery without intravitreal injection history within 3 months preoperatively were enrolled. Patients were randomly divided into three groups based on the medicine injected intraoperatively: Ozurdex, Conbercept, and Control group. The primary outcome is the best-corrected visual acuity (BCVA) within 3 months postoperatively. The secondary outcomes include the intraocular pressure (IOP), mean sensitivity, central retinal thickness and vessels perfusion.Results: The BCVA and the mean sensitivity improved in the three groups (F = 130.8, P 0.05).Conclusion: Compared with the other two groups, anatomical outcomes was improved significantly in Ozurdex group for DR patients. Ozurdex may help to improve the visual acuity and visual sensitivity, and there is no significant difference in the change of IOP and microvascular improvement.Clinical Trial Registration: This trial is registered with the Chinese Clinical Trial Registry (http://www.chictr.org.cn, registration number ChiCTR2100043399).Keywords: proliferative diabetic retinopathy, ozurdex, pars plana vitrectomy, optical coherence tomography angiography, microperimetry

Keywords